San Diego, CA – Biotech company Nanomedical Diagnostics teams with full-service MEMS foundry Rogue Valley Microdevices to deliver the only mass-produced graphene biosensor available, AGILE R100. Previously, the benefits of graphene biosensor technology were restricted to specialized, well-funded university labs building one-off platforms. The new partnership between Nanomedical Diagnostics and Rogue Valley Microdevices has opened the novel sensing technique to any pharmaceutical company seeking to characterize biomolecules quickly and easily, transforming the field of drug discovery.
Graphene has been touted as the world’s most versatile material capable of revolutionizing biomedical applications due to its excellent electrical conductivity, high surface area, and unique biocompatibility. Studies on the detection of biomolecules using lab-produced graphene-based biosensors have shown the sensors to exhibit high sensitivities, wide linear detection ranges, and low detection limits. Numerous efforts have been made by companies to commercialize graphene biosensors at scale, but the process was hampered due to the difficulty of integrating delicate graphene material into standard high-volume production processes.
Nanomedical Diagnostics together with Rogue Valley Microdevices has solved the riddle, overcoming substantial manufacturing hurdles to bring the label-free kinetic binding assay AGILE R100 to market. AGILE R100 is designed to provide biophysical data to pharmaceutical and biotherapeutics companies seeking more informed decisions earlier in the drug discovery process. However, with the most difficult piece of the puzzle – cost-effective large-scale manufacturing – solved, the company plans a significant impact on the healthcare industry with innovative new products that enable cutting-edge life science research, drug discovery applications, and diagnostic and health monitoring platforms.